ArticlemedRxiv : the preprint server for health sciences2026
Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
Treatment toxicity constrains the use of effective cancer therapies, but its clinical and genetic determinants remain poorly defined. We developed a large language model-based approach to produce MSK-Tox, a pan-cancer resource capturing the incidence, temporality, and grade of toxicity to anti-cancer therapy across more than 50,000 patients. Analysis of six representative adverse events-pneumonitis, adrenal insufficiency, liver toxicity, colitis, hyperthyroidism and hypothyroidism-revealed distinct toxicity landscapes shaped by cancer type, treatment regimen, and clinical context. Pretreatment clinical features enabled individualized prediction of toxicity risk across adverse events, supporting risk assessment before therapy initiation. Beyond clinical predictors, we identified two modes of germline susceptibility to treatment toxicity: an organ-intrinsic mode, in which germline variation confers risk across systemic therapies, exemplified by a regulatory variant near
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.